Your browser doesn't support javascript.
loading
A pharmacodynamic/pharmacokinetic study of ficlatuzumab in patients with advanced solid tumors and liver metastases.
Tabernero, Josep; Elez, Maria Elena; Herranz, Maria; Rico, Isabel; Prudkin, Ludmila; Andreu, Jordi; Mateos, Jose; Carreras, Maria Josep; Han, May; Gifford, James; Credi, Marc; Yin, Wei; Agarwal, Shefali; Komarnitsky, Philip; Baselga, Jose.
Afiliação
  • Tabernero J; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York jtabern
  • Elez ME; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Herranz M; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Rico I; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Prudkin L; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Andreu J; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Mateos J; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Carreras MJ; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Han M; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Gifford J; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Credi M; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Yin W; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Agarwal S; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Komarnitsky P; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
  • Baselga J; Authors' Affiliations: Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona; CRC Hospital Quirón de Barcelona, Barcelona, Spain; AVEO Oncology, Cambridge, Massachusetts; and Memorial Sloan-Kettering Cancer Center, New York, New York.
Clin Cancer Res ; 20(10): 2793-804, 2014 May 15.
Article em En | MEDLINE | ID: mdl-24634378
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Hepáticas / Anticorpos Monoclonais / Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Hepáticas / Anticorpos Monoclonais / Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2014 Tipo de documento: Article